Marketed PEGylated Drugs Approved by FDA and in Europe

Creative PEGWorks

An excellent review article is published by scientists from Nektar Therapeutics, Bayer, Jansen, and Baxalta Innovations GmbH in the journal of Journal of Pharmaceutical Sciences.

Journal of Pharmaceutical Sciences 105 (2016) 460-475
Since 1990, 12 PEGylated biopharmaceuticals have been introduced into the market place as drugs for human use (Table 1).Eleven are PEGylated protein biopharmaceuticals and one is aPEGylated aptamer (Macugen) administered intravitreally. Adagen®, Krystexxa®,
Neulasta®, Oncaspar®, PEG-Intron®, Somavert®, and Plegridy® are PEGylated with PEG molecules having molecular weight of 5-20kDa. Cimzia®, Macugen®, Mircera®, Omontys®, and Pegasys®are PEGylated with PEG molecules of 30 or 40 kDa.
Marketed PEGylated Drugs

View original post

Advertisements
Posted in Blogs | Leave a comment

Looking for a better method to improve your PEGylation yield?

Are you looking for a better way to improve your PEGylation yield? I bet you are. Keep reading then……..

Many parameters affect PEGylation process. The surface accessibility of the reactive site of amino acids is the most critical. On protein surfaces, there exist hydrophobic patches and concaves that expel water and thus hydrophilic PEGs. Reactive sites such as cysteine residues can be buried inside the hydrophobic domains. This makes the PEGs hardly contact the free thiols. It has to contact to react. Improving the surface accessibility of reactive sites such as cysteine residues is demonstrated to improve PEGylation efficiency. How to achieve this?

The answer is to temporarily unfold protein structures such as changing pH values, ionic strength or even externally applied stress, all of which could potentially change the protein conformation to allow PEGylation, followed by re-forming the native 3D structure.

Just be smart, and sometimes a bit crazy to try different things. A paper in one ACS journal of Bioconjugate Chemistry doi: 10.1021/acs.bioconjchem.7b00531 solved this problem by applying high pressure to the PEGylation process. At 250 mega-pascals, 90% of protein human ciliary neurotrophic factor (CNTF) was PEGylated without using excess of PEG reagents, which normally have to be used to achieve even a low degree such as 5-10% of PEGylation. Upon PEGylation, the protein reversibly refolds.

Go ahead to try it.

Looking for a better method to improve your PEGylation yield?

Posted in Blogs | Leave a comment

FDA Latest Industry Guidance for Liposome Drug Products

Liposome Drug Products
Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation
It provides specific labeling requirements for liposome versus pegylated liposome.
The nonproprietary name of a drug product approved under the Federal Food, Drug, and Cosmetic Act is its established name, which , in most instances , will be the United States
Pharmacopeia (USP) drug product monograph title for that product. If there is no USP monograph for the liposome drug product, you should refer to 21 CFR 299.4, USP General
Chapter <1121> Nomenclature, and the USP Nomenclature Guidelines. The liposome drug product nonproprietary name should include terminology to express that the product is a liposome or a pegylated liposome. Examples:
[DRUG] Liposome Type X [DOSAGE FORM]
[DRUG] Pegylated Liposome Type X [DOSAGE FORM]
Posted in Blogs | Leave a comment

Nektar – PEGylated opioid analgesic Reported positive Phase 3 clinical trial results

A short polyethylene glycol (PEG) and its pegylation to small molecules could make a huge difference. Nektar announced positive topline results from an oral Human Abuse Potential (HAP) study of NKTR-181, which is a first-in-class opioid analgesic.  NKTR-181 is a pegylated small molecule drug: a short PEG with six repeating ethylene glycol units conjugated to a compound which shares the same core structure with Oxycodone, a semisynthetic opioid. Based on Nektar website, the U.S. Food and Drug Administration (FDA) has granted the investigational medicine NKTR-181 Fast Track designation for the treatment of moderate to severe chronic pain.

“The NKTR-181 HAP study was designed to confirm and assess the relative oral abuse potential of NKTR-181 at its maximum analgesic or therapeutic dose (400 mg) and at a supratherapeutic dose (3 times to 12 times greater than its analgesic dose range of 100 mg to 400 mg) compared to common therapeutic doses of a Schedule II opioid, oxycodone. Its study’s primary efficacy endpoint demonstrated significantly improved chronic back pain relief with NKTR-181 compared to placebo (p=0.0019). Key secondary endpoints of the study also achieved high statistical significance. The study demonstrated that NKTR-181 had a favorable safety profile and was well tolerated.”

Posted in Blogs | Leave a comment

Marketed PEGylated Drugs Approved by FDA and in Europe

An excellent review article is published by scientists from Nektar Therapeutics, Bayer, Jansen, and Baxalta Innovations GmbH in the journal of Journal of Pharmaceutical Sciences.

Journal of Pharmaceutical Sciences 105 (2016) 460-475
Since 1990, 12 PEGylated biopharmaceuticals have been introduced into the market place as drugs for human use (Table 1).Eleven are PEGylated protein biopharmaceuticals and one is aPEGylated aptamer (Macugen) administered intravitreally. Adagen®, Krystexxa®,
Neulasta®, Oncaspar®, PEG-Intron®, Somavert®, and Plegridy® are PEGylated with PEG molecules having molecular weight of 5-20kDa. Cimzia®, Macugen®, Mircera®, Omontys®, and Pegasys®are PEGylated with PEG molecules of 30 or 40 kDa.
Marketed PEGylated Drugs
Posted in Blogs | 1 Comment

Custom Synthesis Options at Creative PEGWorks

green liquid in beaker being added to test tube

Do you need a special PEG reagent synthesized? You’re in luck! At Creative PEGWorks, we handle custom synthesis service for polyethylene glycol (PEG) and other polymers.

Working with a wide variety of functional groups and broad range of molecular weights, we frequently provide custom synthesis of:

  • Functional polymers: Design and synthesis of functional polymer derivatives like polyamino acid, PEG (polyethylene glycol), polyester, and glycosylated and PEGylated biodegradable polymers
  • Small molecules: Design and synthesis of novel organic molecules, API intermediates, stereoisomers, specialty amino acid derivatives, and oligomers
  • Monodispersed PEG: Design and synthesis of monodispersed PEG derivatives with functional groups used in PEGylation chemistry.

When you’re ready to get started with your custom synthesis, contact Creative PEGWorks for a quote.

Posted in Blogs | Leave a comment

Benefits of PEGylation in the Pharmaceutical Industry

covalent bond for polyethylene glycol

Wondering if you should use PEGylation for your products? There are a number of reasons to start using the PEG polymer, including the following benefits:

  • It’s a low-cost additive.
  • It reduces immunogenicity.
  • It provides prolonged residence time.
  • It has improved formulation properties.
  • It can improve product yields.

If you’re looking for a company to handle your PEGylation needs, contact Creative PEG Works, a biotechnology company located in North Carolina. We specialize in PEGylation as well as polymer modification, particle surface functionalization, and custom synthesis of reactive oligomers and polymers of many different molecular weights.

Posted in Blogs | Leave a comment